1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Products
2.2. Quantitative Research
2.2.1. Primary and Secondary Products
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Market Breakdown & Data Triangulation
3. Executive Summary
4. United States Anticoagulation Therapy Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porters Five Forces Analysis
4.3.1. Bargaining End-use Industry of Suppliers
4.3.2. Bargaining End-use Industry of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Intensity of Rivalry
4.4. Recent Development
4.5. PESTEL Analysis
5. United States Anticoagulation Therapy Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.1.1. Drugs
5.2.1.1.1. Novel Oral Anticoagulants (NOACs)
5.2.1.1.2. Warfarin (VKA)
5.2.1.2. PT/INR Testing Devices
5.2.1.2.1. In-Office Testing Devices
5.2.1.2.2. Analyzers
5.2.1.2.3. Reagents and Kits
5.2.1.2.4. Home Testing Devices
5.2.1.3. Service
5.2.1.3.1. Testing Services
5.2.1.3.2. Consulting Services
5.2.2. By Clinic
5.2.2.1. Hospital Associated Clinic
5.2.2.2. Independent Clinics
5.2.2.3. Pharmacy-Based Clinics
6. Competitive Landscape
6.1. List of Key Players and their Offerings
6.2. Company Market Share Analysis, 2021
6.3. Competitive Benchmarking, By Operating Parameters
6.4. Key Strategic Development (Merger, Acquisition, Partnership, etc.)
7. Impact of Covid-19 Across Anticoagulation Therapy Market
8. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
8.1. Bristol-Myers Squibb
8.2. Johnson & Johnson
8.3. Pfizer
8.4. Portola Pharmaceuticals
8.5. C.H. Boehringer Sohn
8.6. Daiichi Sankyo
8.7. Abbott
8.8. Siemens
8.9. Roche
8.10. Alere
8.11. Other Prominent Players
9. Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable